Applied to medicines, price controls would translate into shortages and slow, or non-existent, introduction of new, ...

Bristol-Myers Squibb's Celgene unit has clearly been impressed by progress in its four-year-old alliance with Evotec on protein degradation. It's just paid $200 million to extend the partnership ...